RU2739218C2 - Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы - Google Patents

Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы Download PDF

Info

Publication number
RU2739218C2
RU2739218C2 RU2014145841A RU2014145841A RU2739218C2 RU 2739218 C2 RU2739218 C2 RU 2739218C2 RU 2014145841 A RU2014145841 A RU 2014145841A RU 2014145841 A RU2014145841 A RU 2014145841A RU 2739218 C2 RU2739218 C2 RU 2739218C2
Authority
RU
Russia
Prior art keywords
ser
thr
leu
gly
val
Prior art date
Application number
RU2014145841A
Other languages
English (en)
Russian (ru)
Other versions
RU2014145841A (ru
RU2014145841A3 (enExample
Inventor
Куо-Дзанг КАО
Юнь-Син ВАН
Original Assignee
Серкьюлар Коммитмент Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серкьюлар Коммитмент Компани filed Critical Серкьюлар Коммитмент Компани
Publication of RU2014145841A publication Critical patent/RU2014145841A/ru
Publication of RU2014145841A3 publication Critical patent/RU2014145841A3/ru
Application granted granted Critical
Publication of RU2739218C2 publication Critical patent/RU2739218C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2014145841A 2013-11-15 2014-11-14 Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы RU2739218C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904951P 2013-11-15 2013-11-15
US61/904,951 2013-11-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020129180A Division RU2020129180A (ru) 2013-11-15 2014-11-14 Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы

Publications (3)

Publication Number Publication Date
RU2014145841A RU2014145841A (ru) 2016-06-10
RU2014145841A3 RU2014145841A3 (enExample) 2018-06-25
RU2739218C2 true RU2739218C2 (ru) 2020-12-22

Family

ID=51951740

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014145841A RU2739218C2 (ru) 2013-11-15 2014-11-14 Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы
RU2020129180A RU2020129180A (ru) 2013-11-15 2014-11-14 Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2020129180A RU2020129180A (ru) 2013-11-15 2014-11-14 Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы

Country Status (12)

Country Link
US (6) US9493552B2 (enExample)
EP (1) EP2915545A1 (enExample)
JP (1) JP6538331B2 (enExample)
KR (1) KR102240342B1 (enExample)
CN (1) CN104892767B (enExample)
AU (1) AU2014262247C1 (enExample)
BR (1) BR102014029197B1 (enExample)
CA (1) CA2871114C (enExample)
IL (1) IL235693B (enExample)
RU (2) RU2739218C2 (enExample)
SG (1) SG10201407557VA (enExample)
TW (1) TWI655212B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588587A (en) 2008-03-19 2013-01-25 China Synthetic Rubber Corp Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
CN108997497B (zh) * 2018-03-30 2022-02-25 华兰基因工程有限公司 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用
WO2019195273A1 (en) * 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CN108913709A (zh) * 2018-06-26 2018-11-30 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
CN119700967A (zh) 2019-02-04 2025-03-28 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2021316119A1 (en) 2020-07-31 2023-03-02 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN116239695B (zh) * 2022-05-09 2024-03-22 华兰基因工程(河南)有限公司 特异性结合pv-1蛋白的抗体或其抗原结合片段hlpv-p11及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051105A1 (en) * 2008-10-29 2010-05-06 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
HU220347B (hu) 1994-07-11 2001-12-28 Board Of Regents The University Of Texas System Készítmény az érrendszer specifikus koagulálásához
PT988056E (pt) 1997-01-22 2003-09-30 Univ Texas Metodos e composicoes de factor tecidual para o tratamento da coagulacao e de tumores
US20040067490A1 (en) 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6875570B2 (en) 2000-09-27 2005-04-05 Curagen Corporation Proteins and nucleic acids encoding same
DE10136273A1 (de) 2001-07-25 2003-02-13 Sabine Debuschewitz Molekulare Marker beim hepatozellulären Karzinom
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2603730A1 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP2117591A4 (en) 2007-01-22 2010-11-17 Mayo Foundation REDUCING TUMOR GROWTH
NZ588587A (en) * 2008-03-19 2013-01-25 China Synthetic Rubber Corp Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
JP2011516077A (ja) 2008-04-11 2011-05-26 チャイナ シンセティック ラバー コーポレイション 癌を検出するための方法、薬剤、およびキット
WO2010021822A2 (en) 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
EP3219723B1 (en) * 2009-08-27 2021-10-06 Novo Nordisk A/S Targeting tissue factor to activated platelets
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051105A1 (en) * 2008-10-29 2010-05-06 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HU P. et al., Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis, Cancer Research, 2003, V. 63, N. 16, p. 5046-5053. HERRNBERGER L. et al., The role of plasmalemma vesicle-associated protein (PLVAP) in endothelial cells of Schlemm's canal and ocular capillaries, Experimental eye research, 2012, V. 105, p.27-33. RANTAKARI P. et al., The endothelial protein PLVAP in lymphatics controls the entry of lymphocytes and antigens into lymph nodes, Nature immunology, 2015, V. 16, N. 4, p.386-401. SKERRA A. et al., Assembly of a functional immunoglobulin Fv fragment in Escherichia coli, Science, 1988, V. 240, N. 4855, p.1038-1041. FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein engineering, 2000, V. 13, N. 8, p.575-581. PAKULA A.A. et al., Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N. 1, p.289-310. ЩЁГОЛЕВ А. И. et al., В *

Also Published As

Publication number Publication date
AU2014262247A1 (en) 2015-06-04
RU2020129180A (ru) 2020-10-16
CA2871114C (en) 2023-05-23
IL235693A0 (en) 2015-02-26
RU2014145841A (ru) 2016-06-10
CA2871114A1 (en) 2015-05-15
CN104892767B (zh) 2020-08-21
US20190338016A1 (en) 2019-11-07
US20220372109A1 (en) 2022-11-24
KR20150056489A (ko) 2015-05-26
US11485771B2 (en) 2022-11-01
JP2015096065A (ja) 2015-05-21
RU2014145841A3 (enExample) 2018-06-25
US20250145689A1 (en) 2025-05-08
JP6538331B2 (ja) 2019-07-03
AU2014262247C1 (en) 2020-07-02
TW201609817A (zh) 2016-03-16
KR102240342B1 (ko) 2021-04-14
HK1210788A1 (en) 2016-05-06
US9493552B2 (en) 2016-11-15
BR102014029197A8 (pt) 2018-01-09
US10906959B2 (en) 2021-02-02
IL235693B (en) 2021-09-30
AU2014262247B2 (en) 2019-12-12
US20170000898A1 (en) 2017-01-05
US10400026B2 (en) 2019-09-03
SG10201407557VA (en) 2015-06-29
EP2915545A1 (en) 2015-09-09
US12371473B2 (en) 2025-07-29
BR102014029197A2 (pt) 2016-01-05
CN104892767A (zh) 2015-09-09
NZ701995A (en) 2020-05-29
US20150140021A1 (en) 2015-05-21
TWI655212B (zh) 2019-04-01
US20180362614A1 (en) 2018-12-20
BR102014029197B1 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
US12371473B2 (en) Therapeutic biologic for treatment of hepatocellular carcinoma
KR20200032156A (ko) 항-tim-3 항체 및 이의 용도
AU2019231696A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CN112739716A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
TWI615158B (zh) 多肽之調配物
KR20190057303A (ko) β2-당단백질 1의 수준에 기초한 바비툭시마브에 의한 암 치료 방법, 및 이를 위한 에세이
JP2021529777A (ja) 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
CN116323657A (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2020108636A1 (zh) 全人抗gitr抗体及其制备方法
NZ701995B (en) Therapeutic biologic for treatment of hepatocellular carcinoma
CN115304680A (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
HK1210788B (zh) 用於治疗肝细胞癌的治疗性生物制品
KR20240001136A (ko) IgE 항체를 포함하는 조성물
CN108137680A (zh) 结合犬血管内皮生长因子的抗体及其在治疗犬血管生成相关疾病中的用途
CN116763917A (zh) 一种稳定的抗人il15/pd-l1双功能融合蛋白制剂
CN116333143A (zh) Scube2中和抗体及其医药用途
US20210032340A1 (en) Methods for treating cancer with bavituximab based on levels of beta2-glycoprotein 1, and assays therefor
HK40052936A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190515

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20200304

HZ9A Changing address for correspondence with an applicant